Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “EPI-001 is an autologous dermal papilla cell-based investigational product administered by subcutaneous injection to the scalp for the treatment of androgenetic alopecia.”In the company’s words, NCT07618195 on ClinicalTrials.gov
- Tested for
- Androgenetic Alopecia
- Main trialPhase 1/2
- “This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia. In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration. In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement,…”In the company’s words, NCT07618195 on ClinicalTrials.gov
Other drugs for Androgenetic Alopecia
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up1
- 1 Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Jun 2028 | Study of EPI-001 in Patients With Androgenetic Alopecia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026